EASD 2024: Novo Nordisk’s Saxenda shows weight loss in children
Children aged 6-12 years achieved a 5.8% reduction in BMI with Novo Nordisk's Saxenda at 52 weeks in a Phase IIIa trial.
Children aged 6-12 years achieved a 5.8% reduction in BMI with Novo Nordisk's Saxenda at 52 weeks in a Phase IIIa trial.
What's Your Reaction?
